<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Infection</title>
	<atom:link href="https://www.worldpharmatoday.com/topics/infection/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Sat, 27 Dec 2025 08:25:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>Infection</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON</title>
		<link>https://www.worldpharmatoday.com/press-releases/recipharm-supports-landmark-trial-of-next-generation-pneumococcal-vaccine-developed-by-immbio-and-iicon/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 22 Oct 2025 07:12:45 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Biopharmaceutical Development]]></category>
		<category><![CDATA[Infection]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Vaccination]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/recipharm-supports-landmark-trial-of-next-generation-pneumococcal-vaccine-developed-by-immbio-and-iicon/</guid>

					<description><![CDATA[<p>Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression to phase 2 clinical trials in Malawi. Demonstrates Recipharm’s agility and flexibility, completing full tech transfer, scale-up and process optimisation within three months. Strengthens Recipharm’s position as a trusted partner for innovative and global health collaboration, supporting the development of scalable, affordable vaccines for unmet medical needs. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/recipharm-supports-landmark-trial-of-next-generation-pneumococcal-vaccine-developed-by-immbio-and-iicon/">Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
